News
17 July 2025 – Amsterdam, the Netherlands
Dutch firm Tzu Cancer Therapeutics B.V. acquires Fetch B.V. and gets access to improved isolation method for Circulating Tumor Cells
Tzu Cancer Therapeutics B.V., a startup based on the Amsterdam Science Park, today announces that it has completed the acquisition of Fetch B.V. The deal strengthens Tzu Cancer Therapeutics by providing access to novel technology for isolation of circulating tumor cells from the blood of patients with cancer, developed by Fetch.
MimeCure, winner of the BioBusiness Masterclass Award 2024–2025, receiving the €25,000 prize during the HollandBIO Dutch Biotech Event, 27th of June 2025.
27 June 2025 – Utrecht, the Netherlands
Myosotis proudly supports the next generation of biotech leaders.
At Myosotis, we believe in supporting innovation from the ground up. That’s why we sponsor the award for the BioBusiness Masterclass — this is a unique program that empowers early-stage biotech entrepreneurs and professionals with the tools, network, and insight to grow impactful ventures.
As a long-term partner in the life sciences ecosystem, we see the Masterclass as a key platform to strengthen the future of biotech in the Netherlands and beyond. We’re excited to contribute to a program that bridges science and business, and connects promising talent with seasoned industry experts.
Learn more about the BioBusiness Masterclass on there site: click here
Myosotis Investments B.V.
KVK: 94176795
RSIN: 866665547
Contact
Karpervijver 17, 3703 CJ Zeist, The Netherlands
info@myosotisinvestments.com